Tango Therapeutics Inc
TNGX6.590USD
+0.060+0.92%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
712.43MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Tango Therapeutics Inc Unternehmen
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).
Unternehmensinformationen
BörsenkürzelTNGX
Name des UnternehmensTango Therapeutics Inc
IPO-datumSep 03, 2020
CEODr. Barbara Weber, M.D.
Anzahl der mitarbeiter155
WertpapierartOrdinary Share
GeschäftsjahresendeSep 03
Addresse201 Brookline Avenue
StadtBOSTON
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl02215
Telefon18573204900
Websitehttps://www.tangotx.com/
BörsenkürzelTNGX
IPO-datumSep 03, 2020
CEODr. Barbara Weber, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Mr. Douglas Barry
Mr. Douglas Barry
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
23.55K
-64.32%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
6.25K
--
Mr. Elizabeth Hickin
Mr. Elizabeth Hickin
Vice President, IR and Corporate Communications
Vice President, IR and Corporate Communications
--
--
Dr. Barbara Weber, M.D.
Dr. Barbara Weber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John Ketchum
Mr. John Ketchum
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Mr. Douglas Barry
Mr. Douglas Barry
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
23.55K
-64.32%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Third Rock Ventures, LLC
15.55%
TCG Crossover Management, LLC
9.90%
EcoR1 Capital, LLC
9.81%
Boxer Capital Management, LLC
9.58%
Farallon Capital Management, L.L.C.
6.63%
Other
48.53%
Aktionäre
Aktionäre
Anteil
Third Rock Ventures, LLC
15.55%
TCG Crossover Management, LLC
9.90%
EcoR1 Capital, LLC
9.81%
Boxer Capital Management, LLC
9.58%
Farallon Capital Management, L.L.C.
6.63%
Other
48.53%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
34.87%
Hedge Fund
24.69%
Investment Advisor/Hedge Fund
19.20%
Venture Capital
16.29%
Corporation
11.03%
Individual Investor
1.57%
Research Firm
1.15%
Family Office
0.65%
Private Equity
0.51%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
311
118.45M
109.28%
-17.53M
2025Q1
320
116.84M
107.85%
-22.33M
2024Q4
310
116.06M
107.37%
-22.45M
2024Q3
292
115.54M
108.00%
-9.29M
2024Q2
286
112.62M
105.54%
-13.62M
2024Q1
280
112.63M
105.80%
-9.88M
2023Q4
261
107.66M
105.42%
-11.67M
2023Q3
235
102.78M
102.09%
+4.42M
2023Q2
224
81.67M
92.47%
-10.11M
2023Q1
216
83.27M
94.51%
-3.16M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Third Rock Ventures, LLC
16.86M
15.55%
-194.17K
-1.14%
Apr 01, 2025
TCG Crossover Management, LLC
10.74M
9.9%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
10.63M
9.81%
--
--
Mar 31, 2025
Boxer Capital Management, LLC
10.38M
9.58%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
7.18M
6.63%
+2.57M
+55.76%
Jun 06, 2025
Nextech Invest, Ltd.
5.53M
5.11%
--
--
Mar 31, 2025
Gilead Sciences Inc
4.85M
4.48%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
3.88M
3.58%
-98.30K
-2.47%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.74M
3.45%
-110.35K
-2.87%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.31M
3.06%
-33.10K
-0.99%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
iShares Micro-Cap ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.03%
ProShares UltraPro Russell2000
0.02%
Global X Russell 2000 ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.02%
ProShares Hedge Replication ETF
0.02%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.91%
iShares Micro-Cap ETF
Anteil0.08%
ProShares Ultra Nasdaq Biotechnology
Anteil0.06%
Invesco Nasdaq Biotechnology ETF
Anteil0.06%
iShares Biotechnology ETF
Anteil0.03%
ProShares UltraPro Russell2000
Anteil0.02%
Global X Russell 2000 ETF
Anteil0.02%
iShares Russell 2000 Value ETF
Anteil0.02%
Proshares Ultra Russell 2000
Anteil0.02%
ProShares Hedge Replication ETF
Anteil0.02%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
